18 results about "Disorders skin" patented technology

The present invention relates to compositions comprising at least one lipid-lowering drug or a derivative thereof for the treatment of skin diseases or disorders. In various aspects of the invention, the composition further comprises at least one lipid or a derivative thereof.

The present invention relates to a composition for preventing or treating bladder diseases, a composition for preventing or treating neuropathic pain, neuroinflammation or inflammatory skin diseases, or the therapeutic use of a novel compound YJ102, the compound YJ102 of the present invention inhibits neuropathic pain due to various reasons, ameliorates urination disorders due to spinal cord injury, restores bladder hypertrophy and bladder function, inhibits erythema and keratinogenesis, which are main symptoms of psoriasis, in a psoriasis animal model, and has a superior effect than conventional drugs. The composition can inhibit increase of the thickness of the epidermal layer and spleen hypertrophy caused by psoriasis, and can be used for treating various difficult nervous system diseases or bladder diseases.

The present invention relates to the use of Apoptosis Signal-Regulating Kinase-1 (ASK-1) inhibitor compounds for the treatment of organ diseases and disorders, wherein the organ disease or disorder is selected from a liver, heart disease, kidney, pancreas, spleen, or skin disease or disorder.

The invention provides a novel peptide, CMGN-p1, with skin-regenerating properties. Its origin, synthesis, and functional characterization are described. The peptide consists of a chain of 14 amino acids and stimulates cell proliferation, migration, and adhesion. Its ability to be used as a healing agent for acute and chronic wounds is demonstrated, as it promotes the regeneration and healing of skin and mucous membranes. It may be useful for treating various skin conditions and other related body surfaces.

The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as PAR-2 inhibitors / antagonists, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of pain, an autoimmune disorder, an autoinflammatory disorder, an inflammatory disorder, a central nervous system disorder, spinal cord injury, a metabolic disorder, a gastrointestinal disorder, a cardiovascular disorder, a fibrotic disorder, a respiratory disorder, a skin disorder, an allergic disorder, or cancer.

The present invention provides: an Nrf2 activator; and a pharmaceutical composition for preventing or treating diseases related to activation of Nrf2, comprising the Nrf2 activator. Accordingly, it is possible to effectively prevent or treat oxidative stress- or mitochondrial dysfunction-related neurological diseases or oxidative stress-mediated skin diseases.

A composition comprising fragments of silk fibroin peptides for use in the treatment of a disorder or condition associated with a digestive, pulmonary, or skin disorder. The composition may be also used prophylactically. Several embodiments are proposed in which the composition may be orally administered in a form which prevents unintended degradation of the composition until it reaches a specific point of interest. The composition can be modified to include additional agents for use in the treatment of various disorders of the digestive system, the pulmonary system, or the skin as described herein.

The present invention relates to peptides for the treatment of skin diseases and skin conditions. In particular, the present invention relates to peptides for use in the treatment of wounds and / or vesicles in a patient suffering from a skin disease or skin condition selected from the group consisting of vesicular diseases, diseases or conditions characterized by excessive wound exudate, diseases or conditions characterized by skin microbiome disorders and scars.

This disclosure relates to certain pyrrolopyridone compounds. Certain compounds of the disclosure are potent and selective Bromodomain and Extra-Terminal (BET) inhibitors. The disclosure also relates to pharmaceutically acceptable salts of the compounds or N-oxides thereof, methods of treating diseases and disorders using the compounds, salts, or N-oxides thereof and compositions comprising the compounds salts or N-oxides thereof. The disclosure additionally relates to methods for the treatment of inflammatory and autoimmune diseases and disorders (e.g., skin diseases and disorders, joint and joint-related diseases and disorders, and fibrosis or fibrosis-associated diseases or disorders) using potent and selective BET inhibitors and formulations comprising the disclosed BET inhibitors.

The invention relates to aromatic hydrocarbon receptor modulator compounds represented by the following formula I, respective optical isomers, deuterated compounds, prodrugs or pharmaceutically acceptable salts thereof, and a preparation method and application of the aromatic hydrocarbon receptor modulator compounds and the optical isomers, the deuterated compounds, the prodrugs or the pharmaceutically acceptable salts thereof. The compound can be used as an aromatic hydrocarbon receptor regulator for regulating the activity of an aromatic hydrocarbon receptor in a body, and has very important significance on treatment of related diseases such as immunity, inflammation, infection, skin diseases, osteoporosis, cancers and neurodegenerative diseases.

The present application relates to the application of platynecine in the preparation of drugs for preventing and / or treating skin lesions or tumors. The present application first discovers and verifies the direct inhibitory effect of platynecine on GNAQ mutant protein by constructing a "phenotype-function-target" three-in-one hierarchical screening system, and confirms its broad application prospect in treating diseases mediated by abnormal activation of GNAQ, GNA11 or GNA14 or mutation of related sites. The present application finds that platynecine can be used as a direct inhibitor of GNAQ mutant protein, which breaks the long-standing situation of lack of small molecule direct inhibitors for this target. Through SPR (physical binding) and IP1 (functional blocking) double experimental evidences, it is proved that platynecine is a direct inhibitor of GNAQ, not a broad-spectrum cytotoxic compound. Since the molecular weight of platynecine is moderate (464.6 Da), it is easy to be chemically modified and mass-produced; it has the potential to develop transdermal preparations for external use, providing a new direction for drug treatment of skin diseases such as PWS, to replace or supplement the existing laser therapy.

The present disclosure relates to certain pyrrolopyridone compounds. Certain compounds of the present disclosure are potent and selective bromodomain and out-of-terminal (BET) inhibitors. The disclosure also relates to pharmaceutically acceptable salts of such compounds or N-oxides thereof, methods of treating diseases and conditions using such compounds, salts or N-oxides thereof, and compositions comprising such compounds, salts or N-oxides. The disclosure further relates to methods of treating inflammatory and autoimmune diseases and disorders (e.g., skin diseases and disorders, joints and joint-related diseases and disorders, and fibrosis or fibrosis-related diseases or disorders) using potent and selective BET inhibitors and formulations comprising the disclosed BET inhibitors.

1. The name of the design product: handheld spectrum therapeutic instrument. 2. The use of the design product: for assisting the treatment of inflammatory skin diseases. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The invention discloses an application of sofalcone as a TRPV3 inhibitor in preparation of a medicine for treating skin diseases. Sofalcone has obvious inhibitory activity on TRPV3 ion channel protein and has an obvious anti-pruritus effect on pruritus model mice. The invention provides a certain research basis for developing the targeted TRPV3 inhibitor with a brand-new structure and researching and developing the medicine for treating skin itch.

The present invention relates to a compound of formula (I),whereinX1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N;Y is N or CH;W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N;R1 and R2 are independently of each other(i) a morpholinyl of formula (II)wherein the arrow denotes the bond in formula (I); andwherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue—R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structureswherein the arrows denote the bonds in formula (II); or(ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue —R8R9— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2— or —O—CH2CH2—O—;with the proviso that at least one of R1 and R2 is a morpholinyl of formula II;and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in a method of treating a skin disorder in a subject, wherein said skin disorder is a genodermatosis, a vascular anomaly or a skin disorder selected from scleroderma, sclerodermatous chronic graft-versus-host disease, lichen sclerosus, lichen planus, lichen ruber planus and scars.

Use of antisense thiomorpholino oligonucleotides to treat, prevent, or ameliorate the progression of inflammatory skin diseases or conditions such as psoriasis. Specifically, thiomorpholino¬ containing ASOs that target pre-mRNAs associated with inflammatory skin diseases or conditions such as psoriasis.

The invention relates to the technical field of medicines, in particular to a polypeptide combined preparation with anti-allergy, itching-relieving, anti-inflammatory and repairing functions for treating skin inflammation related diseases. The polypeptide combined preparation is prepared from composite peptide and auxiliary materials, wherein the composite peptide is prepared from acyl dipeptide-1, palmitoyl tripeptide-8, hexapeptide-9, tetrapeptide-3, palmitoyl tripeptide-5, dipeptide-15 and acetyl heptapeptide-4. According to the polypeptide disclosed by the invention, through a trinity action mechanism of resisting allergy, relieving itching and repairing, the skin inflammation problem is improved from multiple dimensions of immune regulation, neural signal blocking, barrier strengthening and the like. Compared with a single component, the multi-target characteristic of the compound is safer and more efficient, the transdermal absorbability is high, and the compound is suitable for being developed into an external preparation (such as emulsion and essence) for skin disease treatment and daily nursing.

Disclosed herein are therapeutic compositions comprising a bacteriophage and colloidal oat flour, and methods of using the compositions in the treatment of skin diseases and conditions, including eczema.